|
EP1979348B1
(en)
*
|
2005-12-21 |
2012-01-18 |
Abbott Laboratories |
Anti-viral compounds
|
|
US7915411B2
(en)
|
2005-12-21 |
2011-03-29 |
Abbott Laboratories |
Anti-viral compounds
|
|
CN101558067B
(zh)
*
|
2006-08-23 |
2014-05-28 |
库多斯药物有限公司 |
作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
|
|
KR101438245B1
(ko)
*
|
2006-08-23 |
2014-09-04 |
쿠도스 파마슈티칼스 리미티드 |
Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체
|
|
US8236950B2
(en)
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
|
JP2010539239A
(ja)
*
|
2007-09-17 |
2010-12-16 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
|
|
WO2009050506A2
(en)
*
|
2007-10-15 |
2009-04-23 |
Astrazeneca Ab |
Combination 059
|
|
CA2710039C
(en)
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
|
WO2009104019A1
(en)
*
|
2008-02-21 |
2009-08-27 |
Astrazeneca Ab |
Combination therapy 238
|
|
US8198441B2
(en)
|
2008-06-20 |
2012-06-12 |
Astrazeneca Ab |
Process for the preparation of novel pyridopyrazines as mTOR kinase inhibitors
|
|
EP2318406B1
(en)
|
2008-07-17 |
2016-01-27 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
AR073354A1
(es)
*
|
2008-07-31 |
2010-11-03 |
Genentech Inc |
Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
|
|
MX2011004585A
(es)
*
|
2008-10-31 |
2011-06-01 |
Novartis Ag |
Combinacion de un inhibidor de fosfatidilinositol-3-cinasa (p13k) y un inhibidor de mtor.
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
CA2781210A1
(en)
|
2009-11-18 |
2011-05-26 |
Novartis Ag |
Methods and compositions for treating solid tumors and other malignancies
|
|
WO2011067356A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Polymorphs of a mek inhibitor
|
|
WO2011067348A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Mek inhibitor salts and solvates thereof
|
|
EP2531194B1
(en)
|
2010-02-03 |
2018-04-18 |
Signal Pharmaceuticals, LLC |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
MX2012009059A
(es)
*
|
2010-02-22 |
2012-09-07 |
Hoffmann La Roche |
Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
|
|
CN102821759A
(zh)
|
2010-03-30 |
2012-12-12 |
诺华有限公司 |
用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
|
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
|
WO2011130232A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
US20130096149A1
(en)
|
2010-06-25 |
2013-04-18 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
|
WO2012099581A1
(en)
|
2011-01-19 |
2012-07-26 |
Takeda Pharmaceutical Company Limited |
Dihydrofuropyrimidine compounds
|
|
CA2843887A1
(en)
|
2011-08-03 |
2013-02-07 |
Signal Pharmaceuticals, Llc |
Identification of gene expression profile as a predictive biomarker for lkb1 status
|
|
CN102911172A
(zh)
*
|
2011-08-04 |
2013-02-06 |
上海恒瑞医药有限公司 |
杂芳基并嘧啶类衍生物、其制备方法和用途
|
|
CN103374021B
(zh)
*
|
2012-04-21 |
2015-10-28 |
通化济达医药有限公司 |
含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
SG10201800741QA
(en)
|
2012-11-29 |
2018-03-28 |
Merck Patent Gmbh |
BENZO-[d][1,2,3]TRIAZINE COMPOUNDS AND USE AS p70S6K INHIBITORS
|
|
TW201521725A
(zh)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
|
|
BR112015026297B1
(pt)
|
2013-04-17 |
2022-08-23 |
Signal Pharmaceuticals, Llc |
Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
|
|
TW201527300A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
|
|
US9937169B2
(en)
|
2013-04-17 |
2018-04-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
|
|
AU2014254052B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
BR112015026292B1
(pt)
|
2013-04-17 |
2022-04-12 |
Signal Pharmaceuticals, Llc |
Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
|
|
US9782427B2
(en)
|
2013-04-17 |
2017-10-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
|
EP3003313A1
(en)
|
2013-05-29 |
2016-04-13 |
Signal Pharmaceuticals, LLC |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
US9512129B2
(en)
|
2014-04-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
TWI700283B
(zh)
*
|
2014-08-04 |
2020-08-01 |
德商拜耳製藥公司 |
２-(嗎啉-４-基)-１,７-萘啶
|
|
CN106008559B
(zh)
*
|
2015-03-25 |
2020-10-16 |
中国科学院上海药物研究所 |
取代吡啶并嘧啶类化合物的合成工艺
|
|
WO2018144791A1
(en)
*
|
2017-02-03 |
2018-08-09 |
Millennium Pharmaceuticals, Inc. |
Combination of vps34 inhibitors and mtor inhibitors
|
|
EP3641772B1
(en)
|
2017-06-22 |
2023-08-02 |
Celgene Corporation |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
|
JP7340519B2
(ja)
*
|
2017-11-06 |
2023-09-07 |
メッドシャイン ディスカバリー インコーポレイテッド |
ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
|
|
WO2021133509A1
(en)
*
|
2019-12-27 |
2021-07-01 |
Angex Pharmaceutical, Inc. |
Heterocyclic compounds as mtor inhibitors
|
|
KR20220140515A
(ko)
|
2020-01-13 |
2022-10-18 |
버지 애널리틱스, 인크. |
치환된 피라졸로-피리미딘 및 그의 용도
|
|
EP4161926A4
(en)
*
|
2020-06-03 |
2024-06-19 |
Yumanity Therapeutics, Inc. |
PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
|
|
CN115968286A
(zh)
*
|
2020-08-26 |
2023-04-14 |
益方生物科技(上海)股份有限公司 |
杂芳基化合物，其制备方法和用途
|
|
CN117088898B
(zh)
*
|
2022-05-13 |
2026-02-06 |
中国药科大学 |
稠环嘧啶类化合物及其制备方法、药物组合物和应用
|
|
WO2024057013A1
(en)
*
|
2022-09-12 |
2024-03-21 |
Exscientia Ai Limited |
Nlrp3 modulators
|